Medicines Position Statements – NEL NEL Access to weight loss medications on the NHS in NEL_ Tirzepatide (Jan 2025) LPP and London Diabetes Network joint statement: Access to continuous glucose monitors for adults living with type 2 diabetes in London IQoro® position statement for hiatus hernia and reflux, stroke-related dysphagia and other indications (NEL)_02.2024 Position statement on generic and brand prescribing (NEL) Preferred DOAC prescribing position statement (NEL)_04.2024